Meridian Bioscience (VIVO) Reports In-Line Q3 EPS of $0.19; Guides
More News related to VIVO
- Meridian Bioscience to Present at the Robert W. Baird 2008 Small Cap Healthcare Conference
- Meridian Bioscience (VIVO) Issues FY09, Reaffirms FY08 Outlook; Intends to Recommend Qtr. Dividend Increase
- Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2009 and Reaffirms Fiscal 2008 Guidance
- Hilliard Lyons Upgrades Meridian Bioscience (VIVO) to Long-Term Buy
- Meridian Bioscience (VIVO) Reports In-Line Q3 EPS of $0.19; Guides
Meridian Bioscience, Inc. (NASDAQ: VIVO) reports Q3 non-GAAP EPS of $0.19, in-line with the analyst estimate of $0.19. Revenues for the quarter were $33.1 million, versus the consensus of $34.58 million.
Reaffirms its FY08 sales guidance of $140-$142 million and EPS in the range of $0.72-$0.75, versus the Street estimates of $141.05 million and $0.74, respectively. Also, Meridian sees double-digit revs and earnings growth for FY09.
Meridian Bioscience, Inc., a life science company, engages in the development, manufacture, sale, and distribution of diagnostic test kits primarily for respiratory, gastrointestinal, viral, and parasitic infectious diseases.
Related Categories
EarningsGuidance
Stocks Mentioned
-0.43Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
